Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of masupirdine for agitation in Alzheimer's disease dementia
2024-513835-25-00Phase 3Authorised
- Sponsor
- Suven Life Sciences
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Masupirdine with Placebo (2 arms). Primary endpoint: Change in CMAI items score aligning to the IPA agitation criteria domains from baseline to Week 12. Planned start Jun 2024; status: authorised.
02
Drugs
masupirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-513835-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513835-25-00.